Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Brenner, Barry
Item TypeName
Academic Article Losartan and end-organ protection--lessons from the RENAAL study.
Academic Article The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy.
Academic Article Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors.
Academic Article The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
Academic Article Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Academic Article Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Academic Article Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Academic Article Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
Academic Article Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Academic Article Dual renin-angiotensin system blockade and kidney disease.
Academic Article Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Academic Article Primary and secondary prevention of chronic kidney disease.
Academic Article Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Academic Article ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
Academic Article Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Academic Article Losartan: lessons learned from the RENAAL study.
Concept Angiotensin II Type 2 Receptor Blockers
Concept Angiotensin II Type 1 Receptor Blockers
Academic Article An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
Academic Article Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Academic Article Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Search Criteria
  • Angiotensin II Type 1 Receptor Blockers
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.